NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2018
At a glance
- Drugs Ensartinib (Primary)
- Indications CNS cancer; Neuroblastoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 31 Aug 2018 Biomarkers information updated
- 09 Apr 2018 Planned End Date changed from 30 Mar 2021 to 30 Sep 2024.
- 09 Apr 2018 Planned primary completion date changed from 30 Mar 2021 to 30 Sep 2024.